Can we improve survival by changing frontline treatments for high-risk medulloblastoma?
Dr Rebecca Hill and her team hope to develop new tools to test chemotherapy options that will combine with radiotherapy to treat high-risk medulloblastoma.
The Little Princess Trust funds research projects in partnership with CCLG, as the founding partner of the CCLG Research Funding Network. CCLG supports the Little Princess Trust to fund world-class scientific research into childhood cancer, sharing our expertise in funding research.
Dr Rebecca Hill and her team hope to develop new tools to test chemotherapy options that will combine with radiotherapy to treat high-risk medulloblastoma.
Professor Darren Hargrave aims to study electrical signals in the brain which could help diffuse midline glioma spread.
Dr Timothy Ritzmann will investigate how proteins that regulate water inside the body could help ependymoma grow and spread.
Professor Owen Williams hopes to develop a combination treatment with a revolutionary new drug that can more effectively fight acute myeloid leukaemia.
Dr Harry Leitch at Great Ormond Street Institute of Child Health will grow early reproductive cells in the lab to understand how germ cell tumours form and help develop new ways to test treatments.
Professor John Anderson will test a new type of CAR T cell therapy designed to help children with solid cancers.
Professor Arturo Sala will test a promising new adult cancer treatment in neuroblastoma to find a kinder and more effective treatment options.
Professor James Arnold is creating a new type of immunotherapy that can fight solid tumours and make it easier for the immune system to help.
Professor Karim Malik aims to test a new combination of drugs that can eliminate neuroblastoma cells.
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.